GC Corporation Overview
GC Corp. is the listed pure holding company at the top of the GC Group, one of South Korea's oldest healthcare groups. Its main asset is a controlling stake in GC Biopharma (KRX: 006280), described as Asia's largest maker of protein therapeutics. GC Biopharma is a leading plasma fractionator and vaccine producer and owns the FDA-approved intravenous immunoglobulin ALYGLO. Around this core the holding company controls or invests in cell therapy (GC Cell), consumer and nutraceutical health (GC Wellbeing, which became a direct holding-company subsidiary in March 2026), US source-plasma collection (ABO Plasma), genomics (GC Genome), healthcare IT and services, and real-estate leasing. The company reports consolidated revenue of about KRW 2.45 trillion for FY2025. Profits have been thin or negative since 2023. The shares trade at roughly half of book value, which is typical of a Korean family-controlled holding company. The investment case rests on ALYGLO's ramp in the US, a turnaround at the subsidiaries, and capital-allocation discipline.
Disambiguation, Japanese GC Corporation (not profiled). The Japanese company was founded on 11 February 1921 in Tokyo as General Chemical Laboratory. It makes dental materials, including glass ionomer cements. The group has more than 3,200 employees and sales activities in more than 100 countries. Since December 2022 it has been run from GC International AG in Lucerne. It is privately held and family-owned, so no market data exists (Lucerne Business; Manufacturing Today; Dental Tribune).
What the company does. GC Corp. is a pure holding company (순수지주회사). It owns, finances and directs subsidiaries across biopharmaceuticals, cell therapy, diagnostics and genomics, consumer health, healthcare IT and services, and property leasing. It earns standalone income from dividends, brand royalties for the "GC" master brand, rental income and management fees. Its consolidated revenue is dominated by GC Biopharma.
Company self-description. Third-party summaries of company filings describe GC Corp. as a biotechnology holding company. Through its affiliates it provides plasma derivatives, prescription drugs, over-the-counter drugs, a Hunter syndrome drug, and vaccines for haemorrhagic fever, varicella, hepatitis B and influenza (Stoxray / S&P-derived profile; Morningstar).
Revenue model mix (consolidated). Butler.works compiles the mix from Q2 2026 filings:
The model is product-led: manufactured plasma derivatives, vaccines and drugs, plus resale of in-licensed products such as Paxlovid distribution in Korea. Service revenue comes from diagnostics, genomic testing, cell-therapy CDMO work and healthcare IT. Subscription-type revenue is modest and sits mainly in healthcare IT. Licensing revenue is episodic and arises from out-licensing of pipeline assets.
Value-chain position. GC is vertically integrated in plasma. It collects source plasma in the US through ABO Plasma and in Korea through the national blood system. It fractionates plasma at Ochang, Korea, and markets finished products in Korea, the US, China, Latin America and the Middle East. In vaccines it runs the full chain from bulk antigen production (Hwasun, Korea) to finished doses. It also sells bulk influenza antigen and finished flu vaccine to international agencies and southern-hemisphere markets.
Customer types. Customers include hospitals and clinics in Korea; specialty pharmacies, infusion centres and group purchasing organisations in the US (ALYGLO); government and NIP buyers for vaccines; international procurement agencies; pharmacies and consumers for OTC products and nutraceuticals; other plasma fractionators (ABO Plasma sells source plasma to third parties); and biotech clients for CDMO and testing.
End-markets. The company serves:
-
Immunology and plasma therapeutics (IVIG, albumin, haemophilia factors)
-
Vaccines (influenza, varicella, Td/Tdap, hepatitis B, Hantaan virus)
-
Rare diseases (Hunter syndrome)
-
Primary-care prescription drugs in Korea
-
Consumer health
-
Cell therapy (NK and CAR-NK)
-
Clinical diagnostics and genomics
-
Healthcare IT
Analyst characterisation. GC Corp. is best understood as a leveraged call on GC Biopharma's plasma franchise, wrapped in a holding-company discount. GC Biopharma provided about 81% of consolidated revenue in FY2025 (KRW 1,991.3 bn of KRW 2,451.5 bn). The remaining subsidiaries add revenue but have dragged on earnings, through losses at GC Cell, start-up losses at ABO Plasma, and impairments. The group's strategic direction since 2023 has been to concentrate on high-margin global products (ALYGLO, Hunterase, Barycela) while restructuring loss-making units. The March 2026 transfer of GC Wellbeing from GC Biopharma to the holding company shows the holding company acting as the group's internal bank.
Strategy
Stated themes from public statements:
-
Becoming a "global leader in the health industry" (Chairman, AGM).
-
"Selection and concentration" on plasma derivatives and high-margin global products (GC group statements, Apr 2026).
-
Improving subsidiary efficiency and earnings structure (GC Biopharma, Jan 2025).
-
Portfolio reshaping at the holding company to raise corporate value (GC Group, Mar 2026).
Medium-term guidance. GC Biopharma's FY2025 operating-profit guidance was cut to the KRW 60 bn range from KRW 70–80 bn. The outcome was about KRW 69 bn. GC Corp. does not publish consolidated guidance in sources reviewed. ESG commitments and quantified cost programmes are not publicly disclosed in sources reviewed.
Products & Services
Note on completeness: GC Biopharma markets well over 100 SKUs. Pricing is not publicly disclosed for any of these products.
Plasma derivatives (GC Biopharma)
| Product | Description | Target customer | Launch / status | Notes |
|---|---|---|---|---|
| ALYGLO (immune globulin intravenous, human-stwk, 10% liquid; IVIG-SN 10%) | IVIG for primary humoral immunodeficiency | US immunologists, infusion centres, specialty pharmacy | FDA approval Dec 2023; US launch Jul 2024 | FY2025 US sales above KRW 150 bn; Q2 2026 KRW 40.5 bn; FY2026 target USD 150 M. A subcutaneous (SC) version is in development, with a BLA targeted for 2031 |
| IVIG-SN (domestic and export IVIG) | Immune globulin 5% / 10% | Hospitals in Korea and export markets | Marketed | Kawasaki disease (mucocutaneous lymph node syndrome) indication noted in profiles |
| Albumin | Plasma volume expander | Hospitals; export (China a key market historically) | Marketed | China exports drove plasma growth historically (Biospectator) |
| Green-VIII inj | Plasma-derived factor VIII for haemophilia A | Haemophilia treatment centres | Marketed | Named in Morningstar profile |
| Antithrombin and other plasma proteins | Specialty plasma proteins | Hospitals | Marketed | Named in Craft profile |
Rare disease
| Product | Description | Target customer | Status | Notes |
|---|---|---|---|---|
| Hunterase (idursulfase-beta) | Enzyme replacement therapy for Hunter syndrome (MPS II) | Rare-disease centres in Korea, MENA, LatAm, Asia | Marketed; ICV (intracerebroventricular) formulation added | FY2025 revenue KRW 74.4 bn (+20%); additional ICV approvals in Japan, Russia and Peru (Alphadistill) |
Vaccines
| Product | Description | Target customer | Status | Notes |
|---|---|---|---|---|
| GC Flu (influenza; quadrivalent moving to trivalent) | Seasonal influenza vaccine; bulk antigen also sold | Korean NIP and private market; southern-hemisphere export; international agencies | Marketed | Shift from quadrivalent to trivalent cut selling prices in 2025 (Hana/Eugene research); Q2 2026 bulk antigen sales pushed into Q3 by delays in WHO strain reference material |
| Barycela (varicella) | Live attenuated chickenpox vaccine | NIP and private paediatric market; export | Marketed | FY2025 revenue KRW 32.1 bn (more than doubled) |
| Hantavax | Hantaan virus (haemorrhagic fever) vaccine | Military and high-risk groups | Marketed | Named in Stoxray profile |
| Hepatitis B vaccine | Recombinant hepatitis B | NIP; export | Marketed | Named in Stoxray profile |
| Td/Tdap vaccines | Tetanus-diphtheria (pertussis) | NIP | Marketed | General record; not re-verified |
Prescription (ETC) and commercial-partner products
| Product | Description | Notes |
|---|---|---|
| Paxlovid (Pfizer COVID-19 antiviral) distribution in Korea | Commercial distribution | Estimated at about KRW 70.3 bn in Q3 2025 (SK Securities preview); lower-margin "merchandise" revenue |
| In-licensed and co-promoted ETC portfolio (cardiometabolic, others) | Primary-care drugs in Korea | — |
OTC and consumer healthcare
| Product | Description | Notes |
|---|---|---|
| Acustop Cataplasma | Topical pain-relief patch | Morningstar profile |
| Zenol Cool Type | Topical analgesic patch | Morningstar profile |
| GC Wellbeing placenta-derived injections (e.g. Laennec-type products) and nutraceuticals | Nutritional and wellness injections, supplements | GC Wellbeing FY2025 revenue KRW 164.7 bn; individual brand names not re-verified |
Cell therapy and CDMO (GC Cell)
| Offering | Description | Status |
|---|---|---|
| AlloNK (allogeneic NK cell programme, partnered with Artiva) | NK cell therapy in combination studies | Alphadistill reports entry into global Phase 3 |
| Immuncell-LC | Autologous T-cell therapy for liver cancer (Korea) | Marketed in Korea (general record; not re-verified) |
| Cell-therapy CDMO and specimen testing | Contract manufacturing; central lab and testing services | Revenue included in GC Cell's KRW 165.5 bn |
Plasma collection (ABO Plasma)
| Asset | Description | Status |
|---|---|---|
| 7 FDA-licensed US plasma centres (California: Calexico and one other; Utah: Orem and one other; New Jersey: Cherry Hill, Glassboro; Texas: Laredo) | Source-plasma collection, for supply to ALYGLO and for third-party sale | 8th centre (Eagle Pass, TX) planned; target is 80% of ALYGLO plasma self-sourced by 2028 |
Diagnostics, genomics and healthcare IT
| Offering | Description | Status |
|---|---|---|
| GC Genome genetic testing | Genomic diagnostics, including NIPT and cancer screening | 9M FY2025 revenue KRW 23.5 bn (+26%) and turned profitable; IPO planned for 2028 |
| Healthcare IT / medical services | EMR and clinic software, medical services | About 9% of GC Corp. consolidated revenue (Q2 2026) |
Financial Narrative
Basis. These are GC Corp. consolidated K-IFRS figures. Primary sources are Butler.works (compiled from DART) and Stoxray (S&P-sourced). FY2024 revenue is derived from FY2025 revenue and the reported +11.2% growth.
Margins and growth (computed)
FY2021 growth is computed against FY2020 revenue of KRW 1,719.3 bn (Stoxray). The four-year revenue CAGR from FY2021 to FY2025 is about 7.4%.
Core subsidiary — GC Biopharma consolidated
Sources: Dailypharm (FY2021); Biospectator (FY2023, -4.9% YoY, which implies the FY2022 base); Kiwoom research, Jan and Apr 2026 (FY2023–FY2025 detail).
Discrepancy: Dealsite (26 Jan 2026) printed FY2025 operating income as KRW 37.0 bn, up 115.3%. A 115.3% increase on KRW 32.1 bn equals about KRW 69.1 bn, which matches Kiwoom. KRW 37.0 bn appears to be the size of the increase, not the level. Dealsite also reported FY2025 net loss of KRW 26.1 bn against Kiwoom's KRW 29.7 bn; these are likely the preliminary and final figures.
GC Biopharma margins (computed):
Balance sheet, cash flow and ratios
Note on the cash-flow sequence: Stoxray lists cash from operations FY2020 KRW 38.1 bn, FY2021 KRW 103.8 bn, FY2022 KRW 97.2 bn, FY2023 KRW -39.7 bn. Alignment to fiscal years is inferred from the matching net-income series.
The following items are not publicly disclosed in sources reviewed:
-
Total assets, total debt (short / long split), net debt and working capital at GC Corp. consolidated level
-
Capex, dividends paid and buybacks
-
ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle
These require the FY2025 DART business report.
Commentary on trends and drivers.
-
Top line. Revenue has compounded at roughly 7% a year, with one flat year (FY2023) that followed the post-COVID fall in vaccine and testing demand. FY2025 was the strongest year (+11.2%). It was driven by ALYGLO's first full commercial year in the US, Hunterase and Barycela, and the first-time consolidation of ABO Plasma.
-
Profit collapse and partial recovery. Operating profit fell from KRW 86.2 bn (FY2021) to losses in FY2023–FY2024, then recovered to KRW 36.2 bn in FY2025. The causes were cost-of-goods inflation in plasma, losses at GC Cell and other subsidiaries, and lower-margin merchandise revenue. The FY2025 recovery mirrors GC Biopharma's operating-profit doubling.
-
Below-the-line drag. Net income has been negative in three of the last three years. Causes include rising interest costs at GC Biopharma (Eugene, Aug 2024), financial-asset valuation losses, and non-cash impairments (GC Cell goodwill in FY2025). This is the central reason the shares trade at about 0.5x book.
-
Working capital intensity. GC Biopharma's inventory rose by about 73% between FY2023 and FY2025 (KRW 516 bn to KRW 892 bn). That reflects plasma stock-building for ALYGLO and is consistent with negative free cash flow per share every year.
-
Inflection watch. Consensus (Kiwoom, Apr 2026) expected GC Biopharma net income to turn positive in FY2026 at KRW 36.8 bn. The weak Q2 2026 makes that dependent on the second half of the year.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship to GC Corp. | Business | Listing |
|---|---|---|---|
GC Biopharma Corp. (GC녹십자) | Core subsidiary. The Holdings group (GC Corp. and 12 related parties) owns about 51.4% | Plasma derivatives, vaccines, prescription drugs, OTC drugs | KOSPI 006280 |
GC Wellbeing (GC녹십자웰빙) | Directly held, 34.5% (largest shareholder) since 31 Mar 2026; previously partly held via GC Biopharma | Nutraceutical injections (placenta-derived products and others), health supplements | KOSDAQ (listed) |
GC Cell (지씨셀) | Consolidated by GC Biopharma | NK and CAR-NK cell therapy, cell-therapy CDMO, specimen testing | KOSDAQ |
ABO Plasma (formerly ABO Holdings) | 100% owned via GC Biopharma's investment vehicle | US source-plasma collection (7 FDA-licensed centres) | Unlisted |
GC Genome | Group affiliate | Genomic diagnostics; IPO targeted for 2028 | Unlisted |
Lymphotec (Japan) | Shares moved from GC Cell to GC Corp. and GC Genome | Japanese cell-therapy business | Unlisted |
GC Care / healthcare IT units | Group affiliates | Medical services and healthcare IT systems (about 9% of consolidated revenue) | — |
Mogam Institute for Biomedical Research | Related non-profit foundation; historically a major shareholder of Holdings | R&D foundation | — |
Revenue by Segment
| Division (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Plasma derivatives revenue KRW Bn | 424.6 | 478.3 | 560.2 |
Vaccines revenue KRW Bn | 265.9 | 256.0 | 300.6 |
Prescription drugs (ETC) revenue KRW Bn | 395.7 | 420.0 | 479.8 |
OTC and consumer healthcare revenue KRW Bn | 123.7 | 121.7 | 119.7 |
Consolidated subsidiaries revenue KRW Bn | 416.8 | 403.9 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Revenue
| Division | FY2024 YoY % | FY2025 YoY % | FY2025 share of standalone divisions % |
|---|---|---|---|
Plasma derivatives | 12.7 | 17.1 | 38.0 |
Vaccines | -3.7 | 17.4 | 20.4 |
Prescription drugs | 6.1 | 14.2 | 32.5 |
OTC / consumer | -1.6 | -1.6 | 8.1 |
Subsidiary Metric Details
| Subsidiary metric (KRW Bn) | FY2025 |
|---|---|
GC Cell revenue | 165.5 |
GC Cell operating profit | -13.8 |
GC Wellbeing revenue | 164.7 |
GC Wellbeing operating profit | 17.3 |
GC Genome revenue 9M | 23.5 |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue KRW Bn | 1,840.6 | 2,079.6 | 2,057.9 | 2,204.6 | 2,451.5 |
Operating income KRW Bn | 86.2 | 71.2 | -16.4 | -10.7 | 36.2 |
Net income (total) KRW Bn | 127.7 | 58.9 | -72.8 | -11.1 | -41.8 |
Basic EPS (controlling) KRW | 1,222 | 709 | -1,210 | 529 | -1,531 |
Revenue per share KRW | 40,694 | 44,920 | 45,997 | 48,548 | 53,993 |
Dividend per common share KRW | — | — | 300 | — | — |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY % | 7.0 | 13.0 | -1.0 | 7.1 | 11.2 |
Operating margin % | 4.7 | 3.4 | -0.8 | -0.5 | 1.5 |
Net margin % | 6.9 | 2.8 | -3.5 | -0.5 | -1.7 |
Financial Analysis — Revenue KRW Bn
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue KRW Bn | 1,537.8 | 1,710.4 | 1,626.6 | 1,679.9 | 1,991.3 |
Operating income KRW Bn | 73.7 | 81.0 | 34.4 | 32.1 | 69.1 |
EBITDA KRW Bn | — | — | 110.3 | 113.1 | 156.8 |
Pre-tax income KRW Bn | — | — | — | -41.1 | -35.3 |
Net income KRW Bn | — | — | -19.8 | -42.6 | -29.7 |
Net income attributable to controlling KRW Bn | — | — | — | -26.3 | -4.7 |
EPS KRW | — | — | — | -2,249 | -400 |
Margin Analysis (%) (FY2023–FY2025)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Operating margin % | 2.1 | 1.9 | 3.5 |
EBITDA margin % | 6.8 | 6.7 | 7.9 |
Financial Analysis — Cash flow from operations
| Item | Latest available | Source |
|---|---|---|
Cash flow from operations (GC Corp. consolidated) | KRW -39.7 bn (FY2023); positive in FY2021 (KRW 103.8 bn) and FY2022 (KRW 97.2 bn) | Stoxray. Sequence alignment inferred; see note |
Free cash flow per share | Negative every year FY2010–FY2025; FY2025 KRW -2,770; TTM KRW -1,169 | roic.ai |
GC Biopharma inventory | KRW 516.2 bn (FY2023), KRW 746.6 bn (FY2024), KRW 891.6 bn (FY2025) | Kiwoom |
GC Biopharma controlling equity | KRW 1,300.2 bn (FY2023), KRW 1,252.6 bn (FY2024), KRW 1,217.5 bn (FY2025) | Kiwoom |
GC Biopharma cash and equivalents (standalone, end FY2025) | About KRW 0.8 bn standalone; Craft reports KRW 49.4 bn at the consolidated level | Dailypharm; Craft |
GC Corp. treasury stock | 4.37% of shares | Butler.works |
ROE (GC Corp., TTM) | -13.42% (Wisesheets, Aug 2026) vs -5.06% (StockHub) | Sources conflict |
P/B | about 0.54x | Butler.works; StockHub |
Revenue by Region
| Overseas line (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
ALYGLO United States revenue KRW Bn | 50 | 150 |
Region Overview
| Region | Principal products / activities | Trend | Reason |
|---|---|---|---|
United States | ALYGLO (IVIG); ABO Plasma source-plasma sales | Fastest-growing | ALYGLO launch Jul 2024; FY2026 target USD 150 M; 7 licensed plasma centres |
South Korea | All segments; dominant share of revenue | Mature, low growth | Price controls on NIP vaccines; flu vaccine shift to trivalent lowered prices |
China | Albumin, IVIG exports | Volatile | Historically strong albumin exports (Biospectator, 2022) |
Middle East / North Africa, Latin America, CIS | Hunterase, plasma products, flu vaccines | Growing | New Hunterase ICV approvals in Japan, Russia, Peru; tender-driven vaccine sales |
Southern hemisphere / international agencies | Influenza vaccine (finished and bulk) | Seasonal, lumpy | Q2 2026 bulk sales delayed to Q3 by WHO strain-reference delays |
Japan | Lymphotec (cell therapy); Hunterase ICV | Early stage | Group plans full-scale entry into Japanese cell therapy via GC Corp. |
Share Price History
| Date | Price | Source |
|---|---|---|
26 Dec 2024 | 17,780 | Stoxray |
17 Apr 2026 | 14,560 (52-week range 12,790–17,700) | Investing.com |
Aug 2026 | 9,960 | Wisesheets |
Q3 2026 | 9,810–10,050 (52-week range 9,490–18,010) | Butler.works; StockHub |
Valuation Multiples
| Multiple | GC Corp. |
|---|---|
P/E | Not meaningful (losses) |
P/B | about 0.54x |
P/S | about 0.19x (market cap about KRW 465 bn / FY2025 revenue KRW 2,451.5 bn) |
Dividend yield | about 3.06% |
Capital Markets
| Metric | FY2016 | FY2023 |
|---|---|---|
Common DPS KRW | 300 | 300 |
Analyst Conclusions
Management guidance. GC Biopharma targets FY2026 ALYGLO revenue of USD 150 M and expects earnings weighted to the second half (the delayed flu bulk shipped in July; Hunterase exports concentrated in H2). ABO Plasma aims to halve its operating loss. No GC Corp. consolidated guidance was found.
Consensus. Kiwoom (Apr 2026) forecast GC Biopharma FY2026 revenue of KRW 1,993.1 bn, operating profit of KRW 71.1 bn and net income of KRW 36.8 bn; for FY2027, revenue of KRW 2,124.6 bn and operating profit of KRW 96.4 bn. No consensus exists for GC Corp.
Bull case
-
ALYGLO scaling toward KRW 300 bn by 2027 with 80% self-sourced plasma could lift group margins from a low base (FY2025 operating margin 1.5%).
-
At about 0.5x book and about 0.2x sales, modest profit normalisation could re-rate the stock.
-
Monetisation options: GC Genome IPO (2028), and an earnings swing from GC Cell, which posted Q2 2026 net income.
Bear case
-
Three consecutive net losses and negative FCF show that growth has not converted into cash.
-
H1 2026 GC Biopharma operating profit fell 61%, and guidance credibility is weak after the FY2025 cut.
-
Holding-company discount, family control and pay controversy limit re-rating potential.
Catalysts and monitorables (next 12 months)
-
Q3 2026 results (late Oct / early Nov 2026): flu bulk and Hunterase recognition
-
Quarterly ALYGLO run-rate against the USD 150 M target
-
Eagle Pass centre licensing
-
ABO Plasma loss trajectory
-
FY2026 dividend decision
-
Any Korea Value-up disclosure or buyback
-
Succession signals
Analyst verdict. GC Corp. is a deep-value but low-quality holding company. Its fortunes are tied almost entirely to GC Biopharma's attempt to become a credible US plasma player. The strategic logic is sound. ALYGLO is a real asset: an FDA-approved IVIG with more than KRW 150 bn of first-full-year sales. Buying ABO Plasma addresses the binding constraint in the business, which is access to plasma. Hunterase and Barycela give the vaccine and rare-disease franchises genuine high-margin products.
Execution and capital efficiency are the problem. Over five years revenue grew about 33%, yet operating profit fell by more than half and the company lost money in each of the last three years. Free cash flow has been negative throughout. Working capital, especially plasma inventory, has absorbed the growth. The holding company has used its cash to support subsidiaries, as in the March 2026 Wellbeing purchase, rather than to reward minority shareholders. Paying the chairman more than KRW 2.4 bn in a loss year shows why governance-sensitive investors apply a steep discount.
The valuation already reflects much of this. At about 0.54x book and 0.2x sales, with a roughly 3% dividend yield, the shares price in a stagnant outcome. The asymmetry depends on whether the second half of 2026 delivers the recovery management has promised. If ALYGLO stays on track for USD 150 M and GC Biopharma returns to positive net income in FY2026, consolidated profits could move from losses to positive territory, and the discount to net asset value could narrow. If it does not, GC Corp. remains a value trap.
The position is best described as speculative accumulation for investors who can monitor quarterly ALYGLO data and Korean governance reform. It is not suitable as a core holding. The deciding evidence will be the Q3 and Q4 2026 results and any formal shareholder-return policy.
SOURCES CONSULTED
-
Hankyung (2 Jan 2018), brand change to GC — https://www.hankyung.com/amp/201801027107f
-
PR Newswire (Jan 2018), GC master brand — https://www.prnewswire.com/de/pressemitteilungen/green-cross-tritt-unter-neuer-muttermarke-gc-auf-667722663.html
-
Dailypharm (29 Mar 2022), English name change to GC Corp. — https://dailypharm.com/user/news/41529
-
Butler.works, GC Corp. financials and filings — https://www.butler.works/ko/companies/00108135
-
Stoxray, 005250 profile — https://stoxray.com/stocks/xkrx/005250
-
roic.ai, 005250 and 005257 — https://www.roic.ai/quote/005250.KS/classic
-
Wisesheets, ROE — https://www.wisesheets.io/roe/005250.KS
-
StockHub, 005250 and pay news — https://stockhub.kr/en/stock/005250 ; https://stockhub.kr/en/news/news_ce73a546bf26
-
Investing.com, 005250 — https://uk.investing.com/equities/green-cross
-
Morningstar AU, 005250 — https://morningstar.com.au/investments/security/XKRX/005250
-
PitchBook profile — https://www.pitchbook.com/profiles/company/53502-76
-
Dealsite (24 Jan 2025; 26 Jan 2026; 7 Apr 2026; 31 Jul 2026; 2019; 2023) — https://dealsite.co.kr/articles/135738 ; /155728 ; /159728 ; /166390 ; /52299 ; /97739
-
Dailypharm (1 Apr 2026), Wellbeing share purchase — https://m.dailypharm.com/user/news/337058
-
Dailian (31 Jul 2026) — https://www.dailian.co.kr/news/view/1673283
-
NewsTomato (31 Jul 2026) — https://newstomato.com/ReadNews.aspx?no=1308906
-
Kiwoom research (Jan and Apr 2026) — https://bbn.kiwoom.com/rfCR11828 ; https://bbn.kiwoom.com/rfCR12014
-
Eugene Investment research (Jul 2024; Aug 2024; Nov 2025) — https://stock.pstatic.net/stock-research/company/63/20251104_company_210558000.pdf
-
SK Securities 3Q25 preview — https://file.alphasquare.co.kr/media/pdfs/company-report/20251020152116843_0_ko.pdf
-
KED Global (12 Dec 2024), ABO acquisition — https://www.kedglobal.com/newsView/ked202412120004
-
PR Newswire / BioSpace (14 May 2025), Calexico approval — https://www.biospace.com/press-releases/gc-biopharma-receives-fda-approval-for-its-u-s-plasma-collection-center-in-calexico-california
-
Biospectator (ABO; Laredo; FY2023 results) — https://www.biospectator.com/news/view/25105 ; /28372 ; /20959
-
Dailypharm English (ABO; Lymphotec) — https://m.dailypharm.com/eng/user/news/24 ; https://m.dailypharm.com/eng/user/news/839
-
Kormedi (CEO appointment) — https://kormedi.com/1222595/
-
Bizhankook, eToday, Dailypharm (ownership history)
-
Alphadistill (FY2025 subsidiary data; partially conflicting) — https://alphadistill.com/report/1860
-
Lucerne Business; Manufacturing Today; Dental Tribune (Japanese GC Corporation disambiguation)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | FY2025 total pay (KRW Bn) |
|---|---|---|---|
Huh Il-seop (허일섭) | Chairman, GC Corp.; also paid by GC Biopharma | Chairman since 2009; youngest son of Hanil Cement founder Huh Chae-kyung; largest shareholder of GC Corp. | 2.413 total (1.193 from GC Corp. + about 1.220 from GC Biopharma) |
Huh Yong-joon (허용준) | CEO and President, GC Corp. | Joined 2003; served in management planning and sales planning, then head of management control (VP); CEO from Mar 2017; Yonsei University; MBA, University of Wisconsin | 2.125 |
Huh Eun-chul (허은철) | President and CEO, GC Biopharma | Son of the late Huh Young-sup; brother of Huh Yong-joon | 1.159 (from GC Biopharma) |
Park Yong-tae (박용태) | Vice Chairman, inside director, GC Corp. | Long-time ally of the chairman; re-elected at the 2017 AGM | — |
Huh Jin-sung (허진성) | Executive, GC Corp. strategy / growth strategy | Eldest son of the chairman | — |
Governance Overview
| Item | Detail |
|---|---|
Chair / CEO separation | Separate roles: Chairman Huh Il-seop and CEO Huh Yong-joon are both registered inside directors and co-representatives (TheVC lists both as 대표) |
Governance flags | (1) Family control with two branches: the chairman's branch and the late co-founder's sons. (2) Executive pay paid while the company is loss-making (Mar 2026 press criticism). (3) Holding company funds subsidiaries through related-party transactions (Wellbeing share purchase, support for GC Care and GC Cell M&A) |
Major Shareholders
| Holder | Stake | As of | Source |
|---|---|---|---|
Huh Il-seop | 12.16% | Sep 2022 | Dealsite |
Mogam Institute for Biomedical Research | 8.73% | Dec 2020 | Dailypharm |
Huh Yong-joon | about 2.65% | 2,018 | Bizhankook |
Huh Eun-chul | about 2.51% | 2,018 | Bizhankook |
Huh Jin-sung | 0.69% | Sep 2022 | Dealsite |
Huh Jin-hoon | 0.64% | Sep 2022 | Dealsite |
Treasury shares | 4.37% | 2,026 | Butler.works |
National Pension Service | — | Jul 2026 | TheVC |
Largest-shareholder group, total | — | Feb 2014 | eToday |
Competitive Landscape
Competitors by Segment
| Segment | Competitors | Positioning of GC |
|---|---|---|
Global plasma / IVIG | CSL Behring (Privigen, Hizentra), Takeda (Gammagard, HyQvia), Grifols (Gamunex-C), Octapharma (Octagam), Kedrion, LFB, Bio Products Laboratory | A small challenger in the US; ALYGLO is a late entrant competing on supply and price |
Korean plasma | SK Plasma | Domestic leader |
Korean vaccines | SK bioscience, Boryung Biopharma, Il-Yang, plus multinationals (Sanofi, GSK) | Leading local flu and varicella supplier |
Rare disease (MPS II) | Takeda (Elaprase), JCR Pharmaceuticals (Izcargo, Japan), Denali (pipeline) | Strong in emerging markets; ICV niche |
Korean prescription drugs | Yuhan, Chong Kun Dang, Hanmi, Daewoong, Dong-A ST | Mid-tier |
Cell therapy | Global NK / CAR-T developers | Early stage |
Korean holding-company peers | Chong Kun Dang Holdings, Dong-A Socio Holdings, Hansol Holdings, Huons Global | Similar discount structure |
Competitor Detail
| Metric | GC Corp. (FY2025) |
|---|---|
Revenue | KRW 2,451.5 bn |
Operating margin | 1.5% |
Revenue growth | 11.2% |
R&D intensity | about 10% (GC Biopharma FY2024) |
Recent Developments
--



